AbbVie to Buy Apogee Therapeutics for $10.9 Billion
Source:
bloombergMarkets
June 22, 2026 · 07:12
Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)
The original article opens on the publisher's website.
More from General
View topic →Australia posts second-quarter growth of 2.1%, beating expectations
cnbc
Sep 1, 2026 · 18:47
Fake 10 Downing Street listing exposes 'unfit' Booking.com, says consumer group
bbcTechnology
Sep 1, 2026 · 18:27
Massachusetts’ 80-year-old senator sees off primary challenge over his age
financialTimes
Sep 1, 2026 · 18:06
Pentagon chaos deepens after Driscoll quits in clash with Hegseth
financialTimes
Sep 1, 2026 · 17:47
Incumbent Sen. Ed Markey wins Massachusetts' Democratic primary for US Senate
nprNews
Sep 1, 2026 · 17:38